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Introduction
Second-hand smoke (SHS) exposure increases adverse health outcomes and is estimated to kill 600,000 people worldwide annually. The World Health Organization (WHO) now recommends that smoke-free indoor public environments are enforced through national legislation. Such regulations have been shown to reduce SHS exposure and consequently, respiratory and cardiovascular morbidity. Evidence of particular health benefit in children is now emerging, including reductions in low birth weight deliveries, preterm birth, and asthma exacerbations. We aim to obtain a comprehensive assessment of the impact of smoke-free legislation on fetal, infant and childhood outcomes, which can inform further development and implementation of global policy and strategies to reduce early life SHS exposure.
Methods
Two authors will search online databases (1975-present) of published and unpublished or in progress studies, and reference lists and citations to articles of interest. We will consult experts in the field to identify additional studies. No language restrictions apply. Studies should describe associations between comprehensive or partial smoking bans in public places and health outcomes among children (0-12 years): stillbirth, preterm birth, low birth weight, small for gestational age, perinatal mortality, congenital anomalies, bronchopulmonary dysplasia, upper and lower respiratory infections, and wheezing disorders including asthma. Cochrane Effectiveness Practice and Organisational Care (EPOC) defined study designs are eligible. Study quality will be assessed using the Cochrane 7-domain based evaluation for randomised and clinical trials, and EPOC criteria for quasi-experimental studies. Data will be extracted by two reviewers and presented in tabular and narrative form. Meta-analysis will be undertaken using fixed-effect or random-effects models depending on the degree of heterogeneity. Adjusted effect estimates will be pooled using generic inverse variance analysis. We will report sensitivity analyses according to study quality and design characteristics, and subgroup analyses according to intervention type, age group, and parental/maternal smoking status. Publication bias will be formally assessed. years. [1, 2] Among non-smoking adults SHS exposure furthermore increases the incidence of asthma, lung cancer and ischaemic heart disease. [2] In an attempt to reduce this substantial burden on second-hand or passive smokers, the World Health Organization (WHO) has recommended that smoke-free indoor public environments are enforced through national legislation and that educational strategies are pursued in parallel to reduce SHS exposure in the home. [3] Studies have since shown that smoking bans effectively reduce SHS exposure, even in absence of an overall decline in smoking prevalence in the population. [4] More importantly, consistent health effects have been reported in a recent Cochrane review summarising 25 studies including reductions in respiratory symptoms, sensory symptoms, and admissions for acute myocardial infarction (AMI). [4] These effects have since been reproduced by others, [5] [6] [7] while additional studies also demonstrated reductions in sudden cardiac arrest and mortality from AMI in response to implementation of smoke-free legislation. [8, 9] As developing individuals, children are particularly vulnerable to the negative effects of SHS, which may even ensue before birth. Furthermore, they are unable to influence their own degree of exposure. Antenatal SHS exposure puts unborn babies at risk for stillbirth, [10] preterm delivery, [11] growth retardation, [12, 13] congenital anomalies, [13, 14] bronchopulmonary dysplasia, [15] and respiratory infections and asthma in childhood. [16, 17] Worldwide at least 40% of children are regularly exposed to SHS after birth, additionally predisposing them to upper and lower respiratory infections as well as asthma. [2] Children thus bear an important part of the disease burden associated with SHS and are likely to particularly benefit from restrictive legislation. Indeed, several recent studies provide evidence for beneficial effects of smoke-free laws on infant and child health. Epidemiological evaluations of the 2006 Scottish smoking ban have demonstrated reductions in low birth weight, childhood asthma hospitalisations, and possibly also preterm birth following its introduction. [18, 19] These results have now been confirmed in several follow-on studies. [20, 21] Despite this increasing evidence for particular health benefits of smoke-free legislation in children, the systematic reviews currently available assessing its health effects in general have not included any studies on perinatal or paediatric outcomes. [4, 22, 23] A comprehensive estimate of the benefits associated with smoke-free legislation in newborns 4 and children will inform the development and implementation of global policy and strategies to further reduce SHS exposure in this particularly vulnerable population. Therefore, we will undertake a systematic review and meta-analysis of studies on fetal, infant, and child health outcomes related to introduction of smoke-free legislation in order to obtain the most comprehensive assessment to date of its effectiveness in improving the health of babies and children worldwide.
METHODS AND ANALYSIS

Design
Systematic review and meta-analysis.
Eligibility criteria
Types of interventions
-Comprehensive (e.g. bars, restaurants and working space) or partial (e.g. working space only) smoking ban in public places at national, state, city, or community level Types of studies -In keeping with Cochrane Effective Practice and Organisation of Care (EPOC) guidelines only the following study designs will be considered for inclusion: (cluster) randomised controlled trials (RCTs), controlled clinical trials (CCTs), quasiexperimental studies, controlled before-and-after studies, interrupted time series (ITS) analysis. [24] For non-randomised studies, comparisons may include either a similarly aged population evaluated in the time frame preceding the introduction of the smoking ban in the same region, or a similar population evaluated during the same time frame in an adjacent geographical area where a smoking ban was not in place.
-Modelling, case-control, cohort, cross-sectional, and uncontrolled before-and-after studies are excluded
Types of participants
-Fetuses > 20 wks gestation -Newborns > 20 wks gestation -Children aged 0-12 years. In order to minimise the confounding effect of selfsmoking, we will restrict our analyses to children aged 12 years and under.
Types of outcome measures
Outcome measures should preferably be reported or documented by a health worker; alternatively, parent-reported outcomes or parent-reported physician diagnoses are 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 o language: none (for foreign language papers translations will be sought)
Study selection
Two authors (JVB, UN) will search databases and screen titles and abstracts for potentially eligible studies. Disagreement will be resolved by consensus, or arbitration involving a third author where necessary. Full text articles will be retrieved for selected studies, and two authors (JVB, UN) will assess whether these meet inclusion criteria. Disagreement will be 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Reasons for exclusion of studies will be noted.
Quality assessment and analysis
Study quality will be assessed using the Cochrane handbook 7-domain based evaluation for RCTs, quasi RCTs and CCTs (Cochrane handbook Table 8 .5.a).
[26] For controlled beforeafter studies and ITS analyses, EPOC guidelines will be used. [27] We will grade each parameter of trial quality: A -low risk of bias; B -moderate risk of bias; C -high risk of bias and an overall assessment for each controlled trial using the same three criteria will be made. Risk of bias will be assessed in part by recording design features (assessed by formal list in Cochrane handbook Table 13 .2.a) as well as whether or not confounding is accounted for.
[26] The primary confounder considered is maternal or parental smoking. Documentation of maternal/parental smoking according to smoke-free legislation status will be assessed, as well as adjustment of the final analyses for a potential confounding effect of this variable. All assessments of study quality will be performed by two authors (JVB, UN) with any disagreement resolved by consensus, or arbitration involving a third author where necessary.
Data extraction
Data will be extracted from selected papers by two reviewers (JVB, UN), with any disagreement resolved by consensus, or arbitration involving a third author where necessary.
The following information will be extracted: 
Data analysis
Data will be presented in tabular and narrative form. If possible, meta-analysis will be performed on similar studies reporting main, primary, and secondary outcomes, and be presented in forest plots. Choice of statistical tests used will depend on the nature of the outcome variable. Application of either a fixed effect or random effects model will be dependent on the degree of heterogeneity. Heterogeneity will be assessed both qualitatively and quantitatively using I² statistic. Where possible, adjusted effect estimates will be pooled in meta-analyses using generic inverse-variance analysis. Adjustment for maternal/parental smoking is mandatory in order for a study to be included in these analyses. Point estimates and 95% confidence intervals will be reported for all analyses.
Sensitivity analyses will be performed in subgroups of study quality and of design characteristics (randomised vs. non-randomised; prospective vs. retrospective). If possible, analyses will be performed in subgroups made according to the following defining parameters: setting of smoking restriction (comprehensive vs. location specific (e.g. working space, bars and restaurants)), age of study subjects (under five years vs. five years and older), smoking status in the home or maternal smoking for perinatal outcomes.
When the number of included studies per outcome is sufficient, publication bias will be assessed visually through Funnel plots and tested by Egger's regression test and Begg's rank correlation test. [28, 29] 
ETHICS AND DISSEMINATION
Ethical issues
As no primary data collection will be undertaken, no additional formal ethical assessment and no informed consent is required.
Publication plan
The systematic review protocol will be registered with PROSPERO International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/prospero). Findings will be summarised in a single manuscript. 
Timeline
AUTHORS' CONTRIBUTIONS
JVB developed the first protocol draft and designed the search strategies. UN was involved in protocol development and search strategy design. OCPvS was involved in protocol development. AS was involved in protocol development and supervised the writing process. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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BMJ Open
Ethics and dissemination
Ethics assessment is not required. Results will be presented in one manuscript. The protocol is registered with PROSPERO Registration number: CRD42013003522 years.[1, 2] Among non-smoking adults SHS exposure furthermore increases the incidence of asthma, lung cancer and ischaemic heart disease. [2] In an attempt to reduce this substantial burden on second-hand or passive smokers, the World Health Organization (WHO) has recommended that smoke-free indoor public environments are enforced through national legislation and that educational strategies are pursued in parallel to reduce SHS exposure in the home. [3] Studies have since shown that smoking bans effectively reduce SHS exposure, even in absence of an overall decline in smoking prevalence in the population. [4] More importantly, consistent health effects have been reported in a recent Cochrane review summarising 25 studies including reductions in respiratory symptoms, sensory symptoms, and admissions for acute myocardial infarction (AMI). [4] These effects have since been reproduced by others, [5] [6] [7] while additional studies also demonstrated reductions in sudden cardiac arrest and mortality from AMI in response to implementation of smoke-free legislation. [8, 9] As developing individuals, children are particularly vulnerable to the negative effects of SHS, which may even ensue before birth. [10] [11] [12] Furthermore, they are unable to influence their own degree of exposure. Antenatal SHS exposure puts unborn babies at risk for stillbirth, [13] preterm delivery, [14] growth retardation, [12, 15] congenital anomalies, [15, 16] bronchopulmonary dysplasia, [17] and respiratory infections and asthma in childhood. [11, 18] Worldwide at least 40% of children are regularly exposed to SHS after birth, additionally predisposing them to upper and lower respiratory infections as well as asthma. [2] Children thus bear an important part of the disease burden associated with SHS and are likely to particularly benefit from restrictive legislation. Indeed, several recent studies provide evidence for beneficial effects of smoke-free laws on infant and child health. Epidemiological evaluations of the 2006 Scottish smoking ban have demonstrated reductions in low birth weight, preterm birth, and childhood asthma hospitalisations following its introduction. [19, 20] These results have now been confirmed in several follow-on studies. [21, 22] Despite this increasing evidence for particular health benefits of smoke-free legislation in children, the systematic reviews currently available assessing its health effects in general have not included any studies on perinatal or paediatric outcomes. [4, 23, 24] A comprehensive estimate of the benefits associated with smoke-free legislation in newborns and children will inform the development and implementation of global policy and strategies 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 to further reduce SHS exposure in this particularly vulnerable population. Therefore, we will undertake a systematic review and meta-analysis of studies on fetal, infant, and child health outcomes related to introduction of smoke-free legislation in order to obtain the most comprehensive assessment to date of its effectiveness in improving the health of babies and children worldwide.
METHODS AND ANALYSIS
Design
Systematic review and meta-analysis. -Modelling, case-control, cohort, cross-sectional, and uncontrolled before-and-after studies are excluded given the difficulty to attribute causation from such studies.
Eligibility criteria
Types of interventions
Types of participants
-Fetuses > 20 wks gestation -Newborns > 20 wks gestation -Children aged 0-12 years. In order to minimise the confounding effect of selfsmoking, we will restrict our analyses to children aged 12 years and under. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 When outcome definitions used in selected reports differ from the criteria outlined above, two authors (JVB and UN) will make a decision regarding their inclusion in any meta-analyses.
Types of outcome measures
This will be based on the degree of deviation from the defined outcome criteria, and the expected effect that this may have on the analyses. A third author will be consulted to resolve any disagreement. Additional sensitivity analyses will be considered to explore the effect of inclusion of different outcome definitions.
Search methods
-Eligible study reports will be identified as follows:
o Published work will be searched for in the following databases: Cochrane 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 o language: none (for foreign language papers translations will be sought)
Study selection
Two authors (JVB, UN) will search databases and screen titles and abstracts for potentially eligible studies. Disagreement will be resolved by consensus, or arbitration involving a third author where necessary. Full text articles will be retrieved for selected studies, and two authors (JVB, UN) will assess whether these meet inclusion criteria. Disagreement will be resolved by discussion amongst reviewers, with referral to a third author if necessary.
Reasons for exclusion of studies will be noted.
Quality assessment and analysis
[27] For controlled beforeafter studies and ITS analyses, EPOC guidelines will be used.[28] We will grade each parameter of trial quality: A -low risk of bias; B -moderate risk of bias; C -high risk of bias and an overall assessment for each controlled trial using the same three criteria will be made. Risk of bias will be assessed in part by recording design features (assessed by formal list in Cochrane handbook Table 13 .2.a) as well as whether or not confounding is accounted for.
[27] The primary confounder considered is maternal or parental smoking. Documentation of maternal/parental smoking according to smoke-free legislation status will be assessed, as well as adjustment of the final analyses for a potential confounding effect of this variable. All assessments of study quality will be performed by two authors (JVB, UN) with any disagreement resolved by consensus, or arbitration involving a third author where necessary.
Data extraction
Corresponding authors of eligible studies will be contacted to clarify any ambiguities. The following information will be extracted: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Data analysis
Data will be presented in tabular and narrative form. If possible, meta-analysis will be performed on similar studies reporting main, primary, and secondary outcomes, and be presented in forest plots. Choice of statistical tests used will depend on the nature of the outcome variable. We will apply a random effects model in all analyses given the expected degree of heterogeneity in population and design between studies. Heterogeneity will be assessed both qualitatively and quantitatively using I² statistic. Meta-analysis will not be undertaken when I² is equal to or greater than 75%. Where possible, adjusted effect estimates will be pooled in meta-analyses using generic inverse-variance analysis. Adjusted effect estimates derived from the most adjusted model in the original paper will be selected for these analyses. Point estimates and 95% confidence intervals will be reported for all analyses.
Sensitivity analyses will be performed in subgroups of study quality and of design characteristics (randomised vs. non-randomised; prospective vs. retrospective). If possible, analyses will be performed in subgroups made according to the following defining parameters: setting of smoking restriction (comprehensive vs. location specific (e.g. working space, bars and restaurants)), age of study subjects (under five years vs. five years and older), smoking status in the home or maternal smoking for perinatal outcomes. For metaanalyses of adjusted effect estimates, an additional sensitivity analysis will be performed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 For any meta-analysis that includes ten or more studies, publication bias will be assessed visually through Funnel plots and tested by Egger's regression test and Begg's rank correlation test. [29, 30] All statistical analyses will be performed using Stata.
ETHICS AND DISSEMINATION
Ethical issues
Publication plan
The systematic review protocol is registered with PROSPERO International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/prospero). Findings will be summarised in a single manuscript.
Timeline
Start date: January 1 st , 2013 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Study quality will be assessed using the Cochrane 7-domain based evaluation for randomised and clinical trials, and EPOC criteria for quasi-experimental studies. Data will be extracted by two reviewers and presented in tabular and narrative form. Meta-analysis will be undertaken using fixed-effect or random-effects models, and generic inverse variance analysis for depending on the degree of heterogeneity. Aadjusted effect estimates will be pooled using generic inverse variance analysis. We will report sensitivity analyses according to study quality and design characteristics, and subgroup analyses according to intervention typecoverage of ban, age group, and parental/maternal smoking status. Publication bias will be formally assessed.
Ethics and dissemination
Ethics assessment is not required. Results will be presented in one manuscript. The protocol is registered with PROSPERO (…). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 years.[1, 2] Among non-smoking adults SHS exposure furthermore increases the incidence of asthma, lung cancer and ischaemic heart disease. [2] In an attempt to reduce this substantial burden on second-hand or passive smokers, the World Health Organization (WHO) has recommended that smoke-free indoor public environments are enforced through national legislation and that educational strategies are pursued in parallel to reduce SHS exposure in the home. [3] Studies have since shown that smoking bans effectively reduce SHS exposure, even in absence of an overall decline in smoking prevalence in the population. [4] More importantly, consistent health effects have been reported in a recent
Cochrane review summarising 25 studies including reductions in respiratory symptoms, sensory symptoms, and admissions for acute myocardial infarction (AMI). [4] These effects have since been reproduced by others, [5] [6] [7] while additional studies also demonstrated reductions in sudden cardiac arrest and mortality from AMI in response to implementation of smoke-free legislation. [8, 9] As developing individuals, children are particularly vulnerable to the negative effects of SHS, which may even ensue before birth. [10] [11] [12] [11, 168, 17] Worldwide at least 40% of children are regularly exposed to SHS after birth, additionally predisposing them to upper and lower respiratory infections as well as asthma. [2] Children thus bear an important part of the disease burden associated with SHS and are likely to particularly benefit from restrictive legislation. Indeed, several recent studies provide evidence for beneficial effects of smoke-free laws on infant and child health. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 to further reduce SHS exposure in this particularly vulnerable population. Therefore, we will undertake a systematic review and meta-analysis of studies on fetal, infant, and child health outcomes related to introduction of smoke-free legislation in order to obtain the most comprehensive assessment to date of its effectiveness in improving the health of babies and children worldwide.
METHODS AND ANALYSIS
Design
Eligibility criteria
Types of interventions
Types of participants
Types of outcome measures
Search methods
o Published work will be searched for in the following databases: Cochrane o language: none (for foreign language papers translations will be sought)
Study selection
Quality assessment and analysis
Study quality will be assessed using the Cochrane handbook 7-domain based evaluation for RCTs, quasi RCTs and CCTs (Cochrane handbook 
Data extraction
Corresponding authors of eligible studies will be contacted to clarify any ambiguities. The following information will be extracted: 
Data analysis
Data will be presented in tabular and narrative form. If possible, meta-analysis will be performed on similar studies reporting main, primary, and secondary outcomes, and be presented in forest plots. Choice of statistical tests used will depend on the nature of the outcome variable. We will apply a Application of either a fixed effect or random effects model in all analyses given the expected degree of heterogeneity in population and design between studies. will be dependent on the degree of heterogeneity. Heterogeneity will be assessed both qualitatively and quantitatively using I² statistic. Meta-analysis will not be undertaken when I² is equal to or greater than 75%. Where possible, adjusted effect estimates will be pooled in meta-analyses using generic inverse-variance analysis. Adjusted effect estimates derived from the most adjusted model in the original paper will be selected for these analyses. Adjustment for maternal/parental smoking is mandatory in order for a study to be included in these analyses. Point estimates and 95% confidence intervals will be reported for all analyses.
Sensitivity analyses will be performed in subgroups of study quality and of design characteristics (randomised vs. non-randomised; prospective vs. retrospective). If possible, analyses will be performed in subgroups made according to the following defining parameters: setting of smoking restriction (comprehensive vs. location specific (e.g. working 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 For any meta-analysis that includesWhen the number of included studies per outcome is sufficient ten or more studies, publication bias will be assessed visually through Funnel plots and tested by Egger's regression test and Begg's rank correlation test.[289, 2930] All statistical analyses will be performed using Stata.
ETHICS AND DISSEMINATION
Ethical issues
Publication plan
The systematic review protocol will beis registered with PROSPERO International Prospective Register of Systematic Reviews (http://www.crd.york.ac.uk/prospero). Findings will be summarised in a single manuscript.
Timeline
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